KIC
ABBV icon

Kensington Investment Counsel’s AbbVie ABBV Stock Holding History

Kensington Investment Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.01M Sell
35,786
-1,727
-5% -$372K 3.91% 3
2026
Q1 		$8.16M Buy
37,513
+492
+1% +$109K 3.93% 3
2025
Q4 		$8.46M Buy
37,021
+858
+2% +$195K 3.44% 4
2025
Q3 		$8.37M Buy
36,163
+548
+2% +$112K 3.41% 5
2025
Q2 		$6.61M Buy
35,615
+1,231
+4% +$229K 2.84% 7
2025
Q1 		$7.2M Buy
34,384
+2,192
+7% +$426K 3.2% 4
2024
Q4 		$5.72M Buy
32,192
+1,320
+4% +$243K 2.39% 9
2024
Q3 		$6.1M Buy
30,872
+316
+1% +$59K 2.55% 6
2024
Q2 		$5.24M Buy
30,556
+1,280
+4% +$212K 2.32% 8
2024
Q1 		$5.33M Buy
29,276
+1,696
+6% +$292K 2.43% 8
2023
Q4 		$4.27M Buy
27,580
+2,742
+11% +$400K 2.24% 9
2023
Q3 		$3.7M Buy
24,838
+783
+3% +$115K 2.3% 6
2023
Q2 		$3.24M Buy
24,055
+2,709
+13% +$397K 2.05% 7
2023
Q1 		$3.4M Sell
21,346
-2,788
-12% -$426K 2.57% 5
2022
Q4 		$3.9M Buy
24,134
+331
+1% +$50.8K 3.06% 3
2022
Q3 		$3.19M Buy
23,803
+1,193
+5% +$171K 2.69% 3
2022
Q2 		$3.46M Sell
22,610
-400
-2% -$61.1K 2.95% 3
2022
Q1 		$3.73M Buy
23,010
+1,149
+5% +$167K 2.47% 3
2021
Q4 		$2.96M Buy
+21,861
New +$2.58M 1.73% 13
2021
Q2 		$2.43M Buy
21,566
+867
+4% +$97.6K 1.67% 15
2021
Q1 		$2.24M Buy
20,699
+2,513
+14% +$269K 1.68% 15
2020
Q4 		$1.95M Buy
+18,186
New +$1.75M 1.61% 14

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kensington Investment Counsel's ABBV Position: Q2 2026 in Review

Kensington Investment Counsel reduced its AbbVie (ABBV) stake by 4.6% in Q2 2026, selling an estimated $372K and leaving 35,786 shares worth $9.01M. The position accounts for 3.91% of the portfolio, ranked #3.

Kensington Investment Counsel first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Kensington Investment Counsel held 35,786 shares of AbbVie worth $9.01M as of Q2 2026.
  • Kensington Investment Counsel sold 1,727 AbbVie shares in Q2 2026, an estimated $372K.
  • AbbVie made up 3.91% of Kensington Investment Counsel's portfolio in Q2 2026, its #3 holding.
  • Kensington Investment Counsel first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kensington Investment Counsel's 13F filing for Q2 2026, filed 14 Aug 2026.